Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib with mFOLFOX6/FOLFIRI for mCRC Conversion Surgery
NCT06010888Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in metastatic colorectal cancer (mCRC), sponsored by Fudan University. Started Oct 2023; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06010888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010888.